Castrate Resistant Prostrate Cancer– Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Castrate Resistant Prostrate Cancer– Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Castrate Resistant Prostrate Cancer: Overview
Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body. Castrate Resistant Prostrate Cancer is defined by disease progression despite androgen-deprivation (ADT) and may present as one or any combination of a continuous rise in serum levels of prostate-specific antigen (PSA), progression of pre-existing disease, or appearance of new metastases. Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body.
Symptoms
The symptoms of Castrate Resistant Prostrate Cancer include:
The patient should be screened early and often using the best available tools to identify potential metastasis and optimize treatment outcomes for patients with metastatic disease. Newer options have been developed that offer increased diagnostic accuracy in patients with Castrate Resistant Prostrate Cancer. These include 18F-sodium fluoride PET-CT, MRI, and CT scans.
Treatment
Immunotherapy with sipuleucel-T should be considered first-line therapy for patients with metastatic Castrate Resistant Prostrate Cancer who are asymptomatic, have low disease burden, and exhibit indolent disease characteristics. Second-generation androgen pathway inhibitors (abiraterone and enzalutamide) should be considered following immunotherapy in the setting of biochemical or clinical progression. Radium Ra 223 dichloride should be considered for patients with bone metastases on the emergence of signs and symptoms of impaired mobility, fatigue, or bone pain. Radium Ra 223 dichloride is an alpha-emitting radionuclide, approved for the treatment with metastatic Castrate Resistant Prostrate Cancer with symptomatic bone metastasis and no known visceral metastasis.
Castrate Resistant Prostrate Cancer Emerging Drugs Chapters
This segment of the Castrate Resistant Prostrate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Castrate Resistant Prostrate Cancer Emerging Drugs
Further product details are provided in the report
Castrate Resistant Prostrate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Castrate Resistant Prostrate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Castrate Resistant Prostrate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Castrate Resistant Prostrate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Castrate Resistant Prostrate Cancer drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Castrate Resistant Prostrate Cancer– Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Castrate Resistant Prostrate Cancer: Overview
Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body. Castrate Resistant Prostrate Cancer is defined by disease progression despite androgen-deprivation (ADT) and may present as one or any combination of a continuous rise in serum levels of prostate-specific antigen (PSA), progression of pre-existing disease, or appearance of new metastases. Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body.
Symptoms
The symptoms of Castrate Resistant Prostrate Cancer include:
- Urinary frequency and urgency
- Fatigue
- Pain/stiffness
- Sexual dysfunction
The patient should be screened early and often using the best available tools to identify potential metastasis and optimize treatment outcomes for patients with metastatic disease. Newer options have been developed that offer increased diagnostic accuracy in patients with Castrate Resistant Prostrate Cancer. These include 18F-sodium fluoride PET-CT, MRI, and CT scans.
Treatment
Immunotherapy with sipuleucel-T should be considered first-line therapy for patients with metastatic Castrate Resistant Prostrate Cancer who are asymptomatic, have low disease burden, and exhibit indolent disease characteristics. Second-generation androgen pathway inhibitors (abiraterone and enzalutamide) should be considered following immunotherapy in the setting of biochemical or clinical progression. Radium Ra 223 dichloride should be considered for patients with bone metastases on the emergence of signs and symptoms of impaired mobility, fatigue, or bone pain. Radium Ra 223 dichloride is an alpha-emitting radionuclide, approved for the treatment with metastatic Castrate Resistant Prostrate Cancer with symptomatic bone metastasis and no known visceral metastasis.
Castrate Resistant Prostrate Cancer Emerging Drugs Chapters
This segment of the Castrate Resistant Prostrate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Castrate Resistant Prostrate Cancer Emerging Drugs
- Niraparib: Janseen
- Nivolumab: Bristol-Myers Squibb
Further product details are provided in the report
Castrate Resistant Prostrate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Castrate Resistant Prostrate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Castrate Resistant Prostrate Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Castrate Resistant Prostrate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Castrate Resistant Prostrate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Castrate Resistant Prostrate Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Castrate Resistant Prostrate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Castrate Resistant Prostrate Cancer
- Novartis in December 2018 announce that it has completed the acquisition of Endocyte, a US biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer.
- Castrate Resistant Prostrate Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Castrate Resistant Prostrate Cancer drugs?
- How many Castrate Resistant Prostrate Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Castrate Resistant Prostrate Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Castrate Resistant Prostrate Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Castrate Resistant Prostrate Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Janseen
- Bristol-Myers Squibb
- AB Science
- Newsoara Biopharma
- ESSA Pharma
- Nirapanib
- Nivolumab
- Masitinib
- ZEN003694
- EPI7386
Introduction
Executive Summary
Castrate Resistant Prostrate Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Castrate Resistant Prostrate Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Castrate Resistant Prostrate Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Niraparib: Janseen
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
ZEN003694: Newsoara Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
EPI7386: ESSA Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Castrate Resistant Prostrate Cancer Key Companies
Castrate Resistant Prostrate Cancer Key Products
Castrate Resistant Prostrate Cancer- Unmet Needs
Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
Castrate Resistant Prostrate Cancer Analyst Views
Castrate Resistant Prostrate Cancer Key Companies
Appendix
Executive Summary
Castrate Resistant Prostrate Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Castrate Resistant Prostrate Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Castrate Resistant Prostrate Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Niraparib: Janseen
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
ZEN003694: Newsoara Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
EPI7386: ESSA Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Castrate Resistant Prostrate Cancer Key Companies
Castrate Resistant Prostrate Cancer Key Products
Castrate Resistant Prostrate Cancer- Unmet Needs
Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
Castrate Resistant Prostrate Cancer Analyst Views
Castrate Resistant Prostrate Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Castrate Resistant Prostrate Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Castrate Resistant Prostrate Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Castrate Resistant Prostrate Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Castrate Resistant Prostrate Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
